Neutralizing antibody to gB2 human cytomegalovirus does not prevent reactivation in patients with human immunodeficiency virus infection

References

1. Adler S. P., Starr S. E., Plotkin S. A., Hempfling S. H., Buis J., Manning M. L., Best A. M. 1995; Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26–32
   [Google Scholar]
2. Alberola J., Dominguez V., Cardenoso L. 7 other authors 1998; Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. J Med Virol 55:272–280
   [Google Scholar]
3. Boppana S. B., Britt W. J. 1995; Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115–1121
   [Google Scholar]
4. Boppana S. B., Polis M. A., Kramer A. A., Britt W. J., Koenig S. 1995; Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis. J Infect Dis 171:182–185
   [Google Scholar]
5. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079–1085
   [Google Scholar]
6. Chou S. W. 1986; Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. New Engl J Med 314:1418–1423
   [Google Scholar]
7. Collier A. C., Chandler S. H., Handsfield H. H., Corey L., McDougall J. K. 1989; Identification of multiple strains of cytomegalovirus in homosexual men. J Infect Dis 159:123–126
   [Google Scholar]
8. Drew W. L., Sweet E. S., Miner R. C., Mocarski E. S. 1984; Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 150:952–953
   [Google Scholar]
9. Rasmussen L. 1999; Molecular pathogenesis of human cytomegalovirus infection. Transpl Infect Dis 1:127–134
   [Google Scholar]
10. Rasmussen L. E., Nelson R. M., Kelsall D. C., Merigan T. C. 1984; Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A 81:876–880
    [Google Scholar]
11. Rasmussen L., Mullenax J., Nelson R., Merigan T. C. 1985; Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol 55:274–280
    [Google Scholar]
12. Rasmussen L., Zipeto D., Wolitz R. A., Dowling A., Efron B., Merigan T. C. 1997; Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. J Infect Dis 176:1146–1155
    [Google Scholar]
13. Snydman D. R. 2001; Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 3 (Suppl. 2):6–13
    [Google Scholar]
14. Urban M., Britt W., Mach M. 1992; The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66:1303–1311
    [Google Scholar]
15. Zipeto D., Morris S., Hong C., Dowling A., Wolitz R., Merigan T. C., Rasmussen L. 1995; Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol 33:2607–2611
    [Google Scholar]
16. Zipeto D., Hong C., Gerna G., Zavattoni M., Katzenstein D., Merigan T. C., Rasmussen L. 1998; Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1–4 in immunocompromised patients. AIDS Res Hum Retroviruses 14:533–536
    [Google Scholar]